The primary function of gp130 signaling in osteoblasts is to maintain bone formation and strength, rather than promote osteoclast formation

Journal of Bone and Mineral Research

Volumn 29, Issue 6, 2014, Pages 1492-1505

  Johnson, Rachelle W ^a   Brennan, Holly J ^a,b   Vrahnas, Christina ^a   Poulton, Ingrid J ^a   McGregor, Narelle E ^a   Standal, Therese ^a,c   Walker, Emma C ^a   Koh, Thuan Tzen ^a   Nguyen, Huynh ^d   Walsh, Nicole C ^a,b   Forwood, Mark R ^d   Martin, T John ^a,b   Sims, Natalie A ^a,b  

^a ST VINCENT'S INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^d GRIFFITH UNIVERSITY   (Australia)

Author keywords

BONE MATRIX; CELL TISSUE SIGNALING; CYTOKINES; ENDOCRINE PATHWAYS; MATRIX MINERALIZATION; OSTEOBLASTS

Indexed keywords

COLLAGEN TYPE 1; GLYCOPROTEIN GP 130; OSTEOCALCIN; SCLEROSTIN; COLLAGEN TYPE I, ALPHA 1 CHAIN; CRE RECOMBINASE; GLYCOPROTEIN; IL6ST PROTEIN, MOUSE; INTEGRASE; OSTERIX PROTEIN, MOUSE; SOST PROTEIN, MOUSE; TRANSCRIPTION FACTOR;

ADIPOCYTE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE GROWTH; BONE MASS; BONE MATRIX; BONE STRENGTH; CELL LINEAGE; COMPARATIVE STUDY; CORTICAL BONE; FEMALE; GENE DELETION; GENE EXPRESSION; MALE; MORPHOMETRICS; MOUSE; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOCLASTOGENESIS; OSTEOCYTE; PHENOTYPE; PRE-CLINICAL IMAGING DEVICE; TRABECULAR BONE; YOUNG MODULUS; ANATOMY AND HISTOLOGY; ANIMAL; BIOLOGICAL MODEL; BONE; BONE DEVELOPMENT; C57BL MOUSE; CELL COUNT; CYTOLOGY; GENE SILENCING; GENETICS; KNOCKOUT MOUSE; METABOLISM; ORGAN SIZE; OSTEOCLAST; REPRODUCIBILITY; SIGNAL TRANSDUCTION;

ANIMALS; BONE AND BONES; CELL COUNT; CELL LINEAGE; COLLAGEN TYPE I; CYTOKINE RECEPTOR GP130; FEMALE; GENE DELETION; GENE KNOCKDOWN TECHNIQUES; GLYCOPROTEINS; INTEGRASES; MALE; MICE, INBRED C57BL; MICE, KNOCKOUT; MODELS, BIOLOGICAL; ORGAN SIZE; OSTEOBLASTS; OSTEOCALCIN; OSTEOCLASTS; OSTEOCYTES; OSTEOGENESIS; REPRODUCIBILITY OF RESULTS; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS;

EID: 84898867547     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.2159     Document Type: Article

References (50)

1. Sims NA, Walsh NC., GP130 cytokines and bone remodelling in health and disease. BMB Rep. 2010; 43 (8): 513-23.
2. Ishimi Y, Miyaura C, Jin CH, et al. IL-6 is produced by osteoblasts and induces bone resorption. J Immunol. 1990; 145 (10): 3297-303.
3. Romas E, Udagawa N, Zhou H, et al. The role of gp130-mediated signals in osteoclast development: regulation of interleukin 11 production by osteoblasts and distribution of its receptor in bone marrow cultures. J Exp Med. 1996; 183 (6): 2581-91.
4. Ishimi Y, Abe E, Jin CH, et al. Leukemia inhibitory factor/ differentiation-stimulating factor (LIF/D-factor): regulation of its production and possible roles in bone metabolism. J Cell Physiol. 1992; 152 (1): 71-8.
5. Poulton IJ, McGregor NE, Pompolo S, Walker EC, Sims NA., Contrasting roles of LIF in murine bone development and remodeling involve region-specific changes in vascularization. J Bone Miner Res. 2012; 27 (3): 586-95.
6. Walker EC, McGregor NE, Poulton IJ, et al. Oncostatin M promotes bone formation independently of resorption when signaling through leukemia inhibitory factor receptor in mice. J Clin Invest. 2010; 120 (2): 582-92.
7. McGregor NE, Poulton IJ, Walker EC, et al. Ciliary neurotrophic factor inhibits bone formation and plays a sex-specific role in bone growth and remodeling. Calcif Tissue Int. 2010; 86 (3): 261-70.
8. Liu F, Aubin JE, Malaval L., Expression of leukemia inhibitory factor (LIF)/interleukin-6 family cytokines and receptors during in vitro osteogenesis: differential regulation by dexamethasone and LIF. Bone. 2002; 31 (1): 212-9.
9. Walker EC, McGregor NE, Poulton IJ, et al. Cardiotrophin-1 is an osteoclast-derived stimulus of bone formation required for normal bone remodeling. J Bone Miner Res. 2008; 23 (12): 2025-32.
10. Wong PK, Quinn JM, Sims NA, van Nieuwenhuijze A, Campbell IK, Wicks IP., Interleukin-6 modulates production of T lymphocyte-derived cytokines in antigen-induced arthritis and drives inflammation-induced osteoclastogenesis. Arthritis Rheum. 2006; 54 (1): 158-68.
11. Poli V, Balena R, Fattori E, et al. Interleukin-6 deficient mice are protected from bone loss caused by estrogen depletion. EMBO J. 1994; 13 (5): 1189-96.
12. Tamura T, Udagawa N, Takahashi N, et al. Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6. Proc Natl Acad Sci U S.A. 1993; 90 (24): 11924-8.
13. Richards CD, Langdon C, Deschamps P, Pennica D, Shaughnessy SG., Stimulation of osteoclast differentiation in vitro by mouse oncostatin M, leukaemia inhibitory factor, cardiotrophin-1 and interleukin 6: synergy with dexamethasone. Cytokine. 2000; 12 (6): 613-21.
14. Palmqvist P, Persson E, Conaway HH, Lerner UH., IL-6, leukemia inhibitory factor, and oncostatin M stimulate bone resorption and regulate the expression of receptor activator of NF-kappa B ligand, osteoprotegerin, and receptor activator of NF-kappa B in mouse calvariae. J Immunol. 2002; 169 (6): 3353-62.
15. Horwood NJ, Elliott J, Martin TJ, Gillespie MT., Osteotropic agents regulate the expression of osteoclast differentiation factor and osteoprotegerin in osteoblastic stromal cells. Endocrinology. 1998; 139 (11): 4743-6.
16. Sims NA, Jenkins BJ, Nakamura A, et al. Interleukin-11 receptor signaling is required for normal bone remodeling. J Bone Miner Res. 2005; 20 (7): 1093-102.
17. Ware CB, Horowitz MC, Renshaw BR, et al. Targeted disruption of the low-affinity leukemia inhibitory factor receptor gene causes placental, skeletal, neural and metabolic defects and results in perinatal death. Development. 1995; 121 (5): 1283-99.
18. Shin HI, Divieti P, Sims NA, et al. Gp130-mediated signaling is necessary for normal osteoblastic function in vivo and in vitro. Endocrinology. 2004; 145 (3): 1376-85.
19. Bellido T, Borba VZ, Roberson P, Manolagas SC., Activation of the Janus kinase/STAT (signal transducer and activator of transcription) signal transduction pathway by interleukin-6-type cytokines promotes osteoblast differentiation. Endocrinology. 1997; 138 (9): 3666-76.
20. Metcalf D, Gearing DP., Fatal syndrome in mice engrafted with cells producing high levels of the leukemia inhibitory factor. Proc Natl Acad Sci U S A. 1989; 86 (15): 5948-52.
21. Li X, Zhang Y, Kang H, et al. Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J Biol Chem. 2005; 280 (20): 19883-7.
22. Tonna S, Sims NA., Talking among ourselves: paracrine control of bone formation within the osteoblast lineage. Calcif Tissue Int. 2014 Jan; 94 (1): 35-45.
23. Rodda SJ, McMahon AP., Distinct roles for Hedgehog and canonical Wnt signaling in specification, differentiation and maintenance of osteoblast progenitors. Development. 2006; 133 (16): 3231-44.
24. Lu Y, Xie Y, Zhang S, Dusevich V, Bonewald LF, Feng JQ., DMP1-targeted Cre expression in odontoblasts and osteocytes. J Dent Res. 2007; 86 (4): 320-5.
25. Betz UA, Bloch W, van den Broek M, et al. Postnatally induced inactivation of gp130 in mice results in neurological, cardiac, hematopoietic, immunological, hepatic, and pulmonary defects. J Exp Med. 1998; 188 (10): 1955-65.
26. Streetz KL, Wustefeld T, Klein C, et al. Lack of gp130 expression in hepatocytes promotes liver injury. Gastroenterology. 2003; 125 (2): 532-43.
27. Sims NA, Clement-Lacroix P, Da Ponte F, et al. Bone homeostasis in growth hormone receptor-null mice is restored by IGF-I but independent of Stat5. J Clin Invest. 2000; 106 (9): 1095-103.
28. Walker EC, Poulton IJ, McGregor NE, et al. Sustained RANKL response to parathyroid hormone in oncostatin M receptor-deficient osteoblasts converts anabolic treatment to a catabolic effect in vivo. J Bone Miner Res. 2012; 27 (4): 902-12.
29. Sims NA, Brennan K, Spaliviero J, Handelsman DJ, Seibel MJ., Perinatal testosterone surge is required for normal adult bone size but not for normal bone remodeling. Am J Physiol Endocrinol Metab. 2006; 290 (3): E456-62.
30. Allan EH, Hausler KD, Wei T, et al. EphrinB2 regulation by PTH and PTHrP revealed by molecular profiling in differentiating osteoblasts. J Bone Miner Res. 2008; 23 (8): 1170-81.
31. Turner CH, Burr DB., Basic biomechanical measurements of bone: a tutorial. Bone. 1993; 14 (4): 595-608.
32. Schriefer JL, Robling AG, Warden SJ, Fournier AJ, Mason JJ, Turner CH., A comparison of mechanical properties derived from multiple skeletal sites in mice. J Biomech. 2005; 38 (3): 467-75.
33. Diez-Perez A, Guerri R, Nogues X, et al. Microindentation for in vivo measurement of bone tissue mechanical properties in humans. J Bone Miner Res. 2010; 25 (8): 1877-85.
34. Sims NA, Dupont S, Krust A, et al. Deletion of estrogen receptors reveals a regulatory role for estrogen receptors-beta in bone remodeling in females but not in males. Bone. 2002; 30 (1): 18-25.
35. Davey RA, Clarke MV, Sastra S, et al. Decreased body weight in young Osterix-Cre transgenic mice results in delayed cortical bone expansion and accrual. Transgenic Res. 2012; 21 (4): 885-93.
36. Karsenty G, Park RW., Regulation of type I collagen genes expression. Int Rev Immunol. 1995; 12 (2-4): 177-85.
37. Kramer I, Halleux C, Keller H, Pegurri M, Gooi JH, Weber PB, Feng JQ, Bonewald LF, Kneissel M., Osteocyte Wnt/beta-catenin signaling is required for normal bone homeostasis. Mol Cell Biol 2010; 30 (12): 3071-85.
38. Xiao Z, Dallas M, Qiu N, et al. Conditional deletion of Pkd1 in osteocytes disrupts skeletal mechanosensing in mice. FASEB J. 2011; 25 (7): 2418-32.
39. Sheng MH, Zhou XD, Bonewald LF, Baylink DJ, Lau KH., Disruption of the insulin-like growth factor-1 gene in osteocytes impairs developmental bone growth in mice. Bone. 2013; 52 (1): 133-44.
40. Cornish J, Callon K, King A, Edgar S, Reid IR., The effect of leukemia inhibitory factor on bone in vivo. Endocrinology. 1993; 132 (3): 1359-66.
41. Sims NA., gp130 signaling in bone cell biology: multiple roles revealed by analysis of genetically altered mice. Mol Cell Endocrinol. 2009; 310 (1-2): 30-9.
42. Burr DB., The contribution of the organic matrix to bone's material properties. Bone. 2002; 31 (1): 8-11.
43. Epelboym Y, Gendron RN, Mayer J, et al. The interindividual variation in femoral neck width is associated with the acquisition of predictable sets of morphological and tissue-quality traits and differential bone loss patterns. J Bone Miner Res. 2012; 27 (7): 1501-10.
44. Mantila Roosa SM, Liu Y, Turner CH., Gene expression patterns in bone following mechanical loading. J Bone Miner Res. 2011; 26 (1): 100-12.
45. Qiu S, Rao DS, Palnitkar S, Parfitt AM., Relationships between osteocyte density and bone formation rate in human cancellous bone. Bone. 2002; 31 (6): 709-11.
46. Bellido T, O'Brien CA, Roberson PK, Manolagas SC., Transcriptional activation of the p21(WAF1,CIP1,SDI1) gene by interleukin-6 type cytokines. A prerequisite for their pro-differentiating and anti-apoptotic effects on human osteoblastic cells. J Biol Chem. 1998; 273 (33): 21137-44.
47. Gabay C, Emery P, van Vollenhoven R, et al. ADACTA Study Investigators. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. Lancet. 2013; 381 (9877): 1541-50.
48. Schwache D, Muller-Newen G., Receptor fusion proteins for the inhibition of cytokines. Eur J Cell Biol. 2012; 91 (6-7): 428-34.
49. Jones SA, Scheller J, Rose-John S., Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling. J Clin Invest. 2011; 121 (9): 3375-83.
50. Waetzig GH, Rose-John S., Hitting a complex target: an update on interleukin-6 trans-signalling. Expert Opin Ther Targets. 2012; 16 (2): 225-36.